Overview

A Phase II Trial of Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a single-armed study designed to evaluate the safety and efficacy of adjuvant targeted-therapy in patients with epidermal growth factor receptor mutation positive stage IB-IIA non-small cell lung carcinoma and high-risk of recurrence following complete tumor resection. The primary endpoint: 2-year DFS rate; The second endpoint: DFS
Phase:
Phase 2
Details
Lead Sponsor:
Tongji University